SVP, General Counsel, CCO Ferraro Joseph Anthony was granted 14,265 shares and returned 38,232 shares to the company, closing all direct ownership in the company (SEC Form 4)

$CTLT
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $CTLT alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ferraro Joseph Anthony

(Last) (First) (Middle)
C/O CATALENT, INC.
14 SCHOOLHOUSE ROAD

(Street)
SOMERSET NJ 08873

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Catalent, Inc. [ CTLT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, General Counsel, CCO
3. Date of Earliest Transaction (Month/Day/Year)
12/18/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/18/2024 D(1) 23,967(2) D (3)(4) 0 D
Common Stock 12/18/2024 A 14,265(5) A $0 14,265 D
Common Stock 12/18/2024 D(1) 14,265 D (6) 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger").
2. Includes restricted stock units ("RSUs").
3. At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $63.50 in cash, without interest (the "Merger Consideration").
4. At the Effective Time, each RSU, whether or not vested, outstanding immediately prior to the Effective Time vested (if unvested) and was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the RSU multiplied by (ii) the Merger Consideration, except for certain RSUs granted following the date of the Merger Agreement which were converted at the Effective Time into restricted cash awards equal to the product of (a) the Merger Consideration multiplied by (b) the number of shares of Issuer common stock subject to such award and otherwise remain subject to their terms, including vesting and acceleration terms.
5. At the Effective Time, each performance stock unit ("PSU"), whether or not vested, outstanding immediately prior to the Effective Time vested based on the greater of (i) the target level of performance or (ii) the actual level of performance as of the Effective Time as determined by the Issuer's board of directors or a committee thereof in its reasonable discretion (other than all then-outstanding awards of PSUs for which the applicable performance period has been completed and the actual level of performance has been certified, in each case, prior to the Effective Time, which vested in accordance with the actual level of performance). PSUs granted with respect to the fiscal 2023-2025 performance period vested at the target level of performance and PSUs granted with respect to the fiscal 2024-2026 performance period vested at 150%, the actual level of performance as of the Effective Time.
6. At the Effective Time, each outstanding PSU was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the PSU as determined in accordance with the Merger Agreement multiplied by (ii) the Merger Consideration.
/s/ Mansi Parikh, attorney-in-fact 12/18/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $CTLT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CTLT

DatePrice TargetRatingAnalyst
11/16/2023$45.00 → $53.00Neutral → Outperform
Robert W. Baird
9/5/2023$62.00Hold → Buy
Argus
7/20/2023$43.00Equal Weight
Wells Fargo
7/5/2023$45.00Neutral
JP Morgan
6/14/2023$45.00 → $44.00Buy → Hold
Jefferies
5/22/2023$90.00 → $45.00Overweight → Neutral
JP Morgan
5/15/2023$55.00 → $29.00Buy → Hold
Deutsche Bank
5/8/2023$28.00Neutral → Underperform
BofA Securities
More analyst ratings

$CTLT
Press Releases

Fastest customizable press release news feed in the world

See more
  • Catalent Announces New Board Appointments

    Adds three new directors with deep expertise across biopharma and life sciences Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings' ownership. Alessandro Maselli, President and CEO, and Board member of Catalent, said "I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech customers. Susan, Marie-France and Tim are each accomplished leaders who bring

    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Lennox International Set to Join S&P 500 and BILL Holdings to Join S&P MidCap 400

    NEW YORK, Dec. 18, 2024 /PRNewswire/ -- S&P MidCap 400 constituent Lennox International Inc. (NYSE:LII) will replace Catalent Inc. (NYSE:CTLT) in the S&P 500, and BILL Holdings Inc. (NYSE:BILL) will replace Lennox International in the S&P MidCap 400 effective prior to the opening of trading on Monday, December 23. Novo Holdings A/S has acquired Catalent in a deal that closed today, December 18. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector Dec 23, 2024 S&P 500 Addition Lennox International LII Industrials Dec 23, 2024 S&P 500 Deletion Catalent CTLT Health

    $BILL
    $CTLT
    $LII
    $SPGI
    EDP Services
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Novo Holdings Completes Acquisition of Catalent

    Catalent to Strengthen its Leading Position as a Global Service Provider for the Pharma and Biotech Industry under Private Ownership Catalent, Inc. ("Catalent"), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S ("Novo Holdings"), a global life sciences investment firm, today announced that Novo Holdings has completed its previously announced acquisition of Catalent in an all-cash transaction with a total enterprise value of approximately $16.5 billion. Alessandro Maselli, who will remain President and Chief Executive Officer of Catalent, said, "The completion of this transaction marks a significant milestone for Catalent.

    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CTLT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CTLT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CTLT
SEC Filings

See more

$CTLT
Leadership Updates

Live Leadership Updates

See more
  • Catalent Announces New Board Appointments

    Adds three new directors with deep expertise across biopharma and life sciences Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings' ownership. Alessandro Maselli, President and CEO, and Board member of Catalent, said "I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech customers. Susan, Marie-France and Tim are each accomplished leaders who bring

    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Lennox International Set to Join S&P 500 and BILL Holdings to Join S&P MidCap 400

    NEW YORK, Dec. 18, 2024 /PRNewswire/ -- S&P MidCap 400 constituent Lennox International Inc. (NYSE:LII) will replace Catalent Inc. (NYSE:CTLT) in the S&P 500, and BILL Holdings Inc. (NYSE:BILL) will replace Lennox International in the S&P MidCap 400 effective prior to the opening of trading on Monday, December 23. Novo Holdings A/S has acquired Catalent in a deal that closed today, December 18. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector Dec 23, 2024 S&P 500 Addition Lennox International LII Industrials Dec 23, 2024 S&P 500 Deletion Catalent CTLT Health

    $BILL
    $CTLT
    $LII
    $SPGI
    EDP Services
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • QuidelOrtho Announces Appointment of Two Independent Directors to its Board

    Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

    $CTLT
    $HYPR
    $NVST
    $QDEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

$CTLT
Financials

Live finance-specific insights

See more
  • Catalent, Inc. Reports First Quarter Fiscal 2025 Results

    Q1'25 net revenue of $1.02 billion increased 4% as reported and in constant currency(1), compared to Q1'24. Q1'25 net revenue, excluding COVID revenue of ~$30 million in Q1'25 and ~$100 million in Q1'24, increased 13% compared to Q1'24. Q1'25 net loss of $(129) million. Q1'25 Adjusted EBITDA(1) of $125 million increased 11% as reported, or 10% in constant currency, compared to Q1'24. (1) See "Non-GAAP Financial Measures" below and the GAAP to non-GAAP reconciliation provided later in this release. Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the first quarter of fisc

    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results

    Q4'24 net revenue of $1.30 billion increased 23% as reported, or 24% in constant currency, compared to Q4'23. Organic, constant-currency net revenue increased 24%, compared to Q4'23. Q4'24 net revenue, excluding COVID-related revenue of ~$70 million in Q4'23 and ~$30 million in Q4'24, increased 29% compared to Q4'23. Fiscal 2024 net revenue of $4.38 billion increased 3% as reported, or 2% in constant currency, compared to fiscal 2023. Organic, constant-currency net revenue increased 1% compared to FY'23. FY'24 net revenue, excluding COVID-related revenue of ~$630 million in FY'23 and ~$260 million in FY'24, increased 13% compared to FY'23. Q4'24 net earnings of $23 million

    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Catalent, Inc. Reports Third Quarter Fiscal 2024 Results

    Q3'24 net revenue of $1.07 billion increased 4% as reported, or 3% in constant currency(1), compared to Q3'23. Q3'24 net revenue, excluding COVID-related revenue of ~$120 million in Q3'23 and ~$60 million in Q3'24, increased 11% compared to Q3'23. Q3'24 net loss of $(101) million compared to $(227) million of net loss in Q3'23. Q3'24 Adjusted EBITDA(1) of $163 million increased 55% as reported, or 53% in constant currency, compared to Q3'23. (1) See "Non-GAAP Financial Measures" below and the GAAP to non-GAAP reconciliation provided later in this release. Catalent, Inc. (NYSE:CTLT) ("Catalent"), the leader in enabling the development and supply of better treatments for patien

    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CTLT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more